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. Sixty-eight years and a few chemical modifications later nitrogen mustards such as cyclophosphamide and melphalan are still front-line chemotherapeutic agents in the treatment of leukaemia, as well as solid tumours. Nitrogen mustards were joined in the clinical treatment of cancer by mitomycin C (MMC) in 1956, platinum compounds such as cisplatin in 1971 and psoralens in 1989. Although these drugs all showed remarkable anticancer properties, it was not known that they function by inducing interstrand crosslinks (ICLs) until well after their introduction as chemotherapy. Only within the past few years has it become clear how cells can recognize, repair and ultimately develop resistance to ICL-inducing agents, and how this allows tumour regrowth.
The separation of the two strands of a DNA double helix is essential for cellular processes such as replication and transcription. ICLs are extremely toxic to cells because they prevent this separation, by coordinated chemical reactions with bases on opposing strands. The resulting covalent linkage is usually irreversible. Covalent crosslinks between bases in the same DNA strand, which are known as intrastrand crosslinks, can also arise. Such damage can be bypassed by some DNA polymerases, making this type of lesion less toxic during replication than crosslinks between the two DNA strands.
The mechanism of action of all interstrand crosslinking drugs is broadly similar
. Each ICL-inducing agent exhibits different base specificity and, as discussed below, the resulting structural changes in the DNA can result in rather different cellular responses. The structure of some of these drugs crosslinked to DNA bases, and their clinical usage, is highlighted in TABLE 1. In this Review we detail how complex networks of DNA repair processes are coordinated to repair ICLs. We also describe how defects in these repair processes can cause cancer but can also sensitize established cancers to ICL-based chemotherapy.
ICLs and cancer initiation
Although the clinical use of DNA crosslinking drugs in killing cancer cells is well established (FIG. 1) , it is less clear whether DNA crosslinking presents a cause of cancer. One reason for this is that ICL-inducing drugs generally cause a wide variety of DNA lesions in addition to crosslinks. For example, cisplatin, the most widely used crosslinking drug, causes damage that is estimated to comprise of 90% intrastrand crosslinks (predominantly crosslinks between adjacent purine residues on the same strand of the DNA double helix) and
Lipid peroxidation
The oxidation of fats and oils to form radicals capable of crosslinking DNA. It can occur in foods before they are eaten or can take place in the body.
Radial chromosome
A structure thought to result from the fusion of the broken arms of non-homologous chromosomes. Such chromosomes cannot be properly segregated in most cells, resulting in either chromosome breakage or a failure in cell division. less than 5% ICLs 2 . MMC and alkylating agents, such as the nitrogen mustards, also typically only cause 5-10% ICLs 3 . Furthermore, exposure to such drugs is generally in a clinical setting -there is very little evidence to suggest exposure to high levels of natural sources of ICL-inducing agents.
The most well-characterized potential sources of ICLs in nature are the by-products of lipid peroxidation, including acrolein and crotonaldehyde R, β-unsaturated aldehydes 4, 5 , the concentrations of which could increase with a high-fat diet or with alcoholism 6, 7 . Other sources could include abasic sites, natural psoralens (such as those found in bergamot, celery and parsley) and even oestrogens [8] [9] [10] [11] [12] . Pre-cancer phenotypes such as hyperplasia and cell atypia are found to be more severe in mice that are treated with photoactivatable bifunctional psoralens (which are able to form crosslinks) than when closely related, but monofunctional, agents are used 13 ; this is despite the fact that bifunctional agents cause a similar number of point mutations to monofunctional agents when assayed in vitro 14 . One interpretation is that, although ICLs inhibit strand separation, their repair proceeds via a pathway that causes point mutations but also other tumour-promoting lesions, such as deletions and translocations.
Sadly, the Italian inhabitants of Bari harbour went on to have a much higher incidence of cancers, specifically leukaemias, in the aftermath of the S.S. John Harvey bombing 15 . An increased incidence of acute myeloid leukaemia (AML) is also seen in patients who undergo therapeutic treatment with ICL-inducing drugs 16, 17 . The blood seems to be specifically sensitive to both the carcinogenic and the chemotherapeutic effects of ICLs, and we have come some way in understanding the molecular details of these events by analysis of the genetic disorder known as Fanconi anaemia (FA).
Cancer that is associated with FA FA is a rare inherited syndrome that is characterized by sub-fertility, congenital abnormalities, progressive bone marrow failure and a highly elevated risk of haematological and squamous cell cancers 18 . The disease is genetically heterogeneous, and 14 complementation groups have so far been identified after exhaustive genetic and functional complementation studies 19, 20 . All of the products of the FA genes are thought to act in a common cellular pathway, and at least seven (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG and FANCL) form a complex that is known as the FA core complex. Diagnosis of FA involves the cytogenetic analysis of lymphocytes that have been treated with ICL-inducing agents -FA-positive cells show highly increased levels of chromosome aberrations, including chromosome breakage and radial chromosome formation 21 . FA cells are also hypersensitive to ICL-inducing agents, and the management of cancer in patients with FA must strictly exclude treatment with these drugs.
Although the majority of reported cases of FA are due to mutations in FANCA (65%), FANCC (15%) or FANCG (10%) (see the Fanconi Anaemia Mutation Database; see Further information), the range of both clinical outcome and cancer susceptibility in each of the groups is broadly similar (except for the BRCA2 (also known as FANCD1) and partner and localizer of BRCA2 (PALB2; also known as FANCN) subgroups, as detailed below). Bone marrow failure is the most common symptom, and this can be readily treated with human leukocyte antigen (HLA)-matched transplant. In this regard, the autologous transplant of gene-corrected stem cells may be possible in the near future 22 . Unfortunately, many patients with FA develop AML before a stem cell transplant can take place, with a >700-fold risk of developing AML compared with the general population 23 . In one study, the actuarial risk of developing haematopoietic abnormalities was 98%, and the risk specifically for AML was 52% by the age of 40 years in patients with FA 24 . Solid tumours are also present at early onset and represent a greater risk in patients with FA, with the most common being head and neck squamous cell carcinoma (HNSCC; 700-fold elevated risk), as well as oesophageal (2,300-fold increased risk) and gynaecological (>180-fold increased risk) cancers 23 . There are, however, some differences in the cancer susceptibilities that are associated with the various complementation groups. For example, patients with PALB2 or BRCA2 mutations seem to be prone to cancer earlier in life, and there is a high proportion of cases of medulloblastoma in patients with FANCD1 (REFS 25, 26) . Cancer mortality was close to 100% by 5 years of age for children with biallelic BRCA2 mutations and in seven families with PALB2 mutations 27, 28 . Other groups, such as those with mutations in FANCM, FANCL and RAD51C (also known as FANCO) have no cancer probands but this is probably due to the very low incidence of individuals with a mutation in these genes [29] [30] [31] . Within the most prevalent complementation group there have been descriptions of highly cancer-prone families who have been associated with particular FANCA mutations, but a larger population-based study has shown that the most prevalent 'hot spots' within FANCA are actually founder mutations 25, 32 . Unfortunately, although the majority of the leukaemia predisposition is removed when patients receive donor transplants, patients with FA often go on to develop extremely aggressive HNSCCs with 40% cumulative incidence by the age of 40 years. Two-year survival rates in such individuals are less than 50% 33 . The origin of cancers in patients with FA has been a topic of debate, and given that some form of bone marrow failure precedes many sporadic leukaemias 34 , it is one that may apply to some sporadic cancers. Although Fanca
Fancm
-/-and Fancd2 -/-mice all show mildly elevated tumour incidence 35 , no research undertaking has determined whether this incidence increases with low-dose exposure to agents such as MMC. Furthermore, laboratory animals that are raised in a highly controlled setting may not be exposed to environmental sources of ICLs. The severe genetic instability of FA cells (both mouse and human) exposed to interstrand crosslinking agents nonetheless suggests several potential routes to tumour development.
First, the genetic instability of FA cells would make them more prone to the translocation of oncogenes or the deletion of tumour suppressor genes. Interestingly, the incidence of point mutations seems to be somewhat decreased in FA cells, but genomic rearrangements,
Box 1 | Mechanism of interstrand crosslink formation by commonly used chemotherapeutic agents
The mechanisms of action of the four main classes of crosslinking drugs (alkylating agents, platinums, mitomycin C and furocoumarins, and psoralens) are broadly similar in that two chemically active leaving groups are required. In bifunctional nitrogen mustards and platinum compounds these leaving groups are acquired inside the cell by the sequential displacement of two chloride ions by water molecules (see part a of the figure). This activated form of the drug can react with bases on each DNA strand, most commonly the N 7 -position of guanosine or adenosine (highlighted in orange in the figure) 151 . Mitomycin C and psoralens are natural products originally derived from fungal sources that form DNA crosslinks more directly. Mitomycin C and psoralens both contain planar rings that are activated by photon-mediated cycloaddition or cycloreduction, respectively, to attack DNA bases on opposing strands (see parts b and c of the figure). Monoadducts, in which the agent remains linked to one rather than two DNA strands, can also form if a water molecule accepts the second free leaving group. Psoralen is particularly useful for targeted tumour therapy, as its crosslinking ability is only activated in response to treatment with ultraviolet A (UVA) radiation.
including a selection of specific and oncogenic translocations such as loss of 1q and 3q and monosomy on chromosome 7, are favoured [36] [37] [38] . It has been suggested that a single unrepaired ICL that arises spontaneously in DNA could be enough to induce an oncogenic translocation in an FA cell 39, 40 . Second, the induction of apoptosis by unrepaired DNA damage leads to increased cell death in the haemato poietic system of patients with FA and in knockout mouse models 41, 42 . This leads to the depletion of the haematopoietic stem cell pool, which is analogous to the depletion that is seen in other DNA repair defective disorders 43 . The repeated proliferation of the remaining haematopoietic stem cells in order to maintain tissue homeostasis leads to the rapid selection of tumorigenic clones. At least in mice, such clones have increased resistance to apoptosis-inducing cytokines, and these tumorigenic clones can accumulate excessive translocations 44 . In this manner, the increased genomic instability and selective pressure for resistance to apoptosis may combine to drive tumorigenesis in patients with FA.
A third potential mechanism of tumour susceptibility in patients with FA has recently been suggested that may account for the unusually high incidence of HNSCCs 45 . The accumulation of unrepaired ICLs induces a transient arrest at the G2 phase of the cell cycle, presumably until the ICLs have been removed 46 . In FA cells, this G2 arrest is considerably extended and may make them more susceptible to Epstein-Barr virus (EBV) and human papilloma virus (HPV) infection -a potent source of oncogenic activation. These viruses preferentially integrate into regions of the genome that have stalled replication 47 . In a sample of 25 American patients with FA-associated head and neck cancers, 85% of tumours Nucleotide excision repair (NER). Nucleolytic removal of a damaged nucleotide by sequential action of 5′-and 3′-endonucleases followed by polymerase-mediated filling of the resulting gap.
Translesion synthesis (TLS).
A DNA damage tolerance process that allows replication past DNA lesions. If the normal replicative polymerase cannot insert a base owing to damage in the template strand, it is often replaced by a lower fidelity translesion polymerase.
Replisome
The active and assembled structure that contains the enzymes required for DNA replication.
were found to be positive for HPV DNA 48 (although a similar European follow-up study found only 10% 49 ). If other studies provide support for the link between the failure to repair ICLs and HPV-associated HNSCC, it may also explain why young cancer patients who receive ICL-inducing chemotherapy have an increased incidence of head and neck cancers in later life 42 . The failure to repair ICLs and the consequent tumorigenesis in individuals with FA indicate that the FANC genes are essential for an ICL repair pathway, especially as inherited or targeted defects in many DNA repair genes can lead to ICL sensitivity and, in many cases, cancer-prone disorders that are similar to FA (TABLE 2) . FA has thus become a model disease for the understanding of ICL repair, and the FA pathway is now thought to involve the coordination of several repair systems, including homologous recombination (HR), nucleotide excision repair (NER) and translesion synthesis (TLS). The essence of the ICL repair pathway is highlighted in FIG. 2 , and the various elements are discussed below.
Activation of coordinated ICL repair
Seven of the FA gene products are known to form the FA core complex, which contains ubiquitin ligase activity owing to the FANCL component. Other proteins in the complex are orphans with no known functional domains but with many coiled-coil regions (reviewed in REF. 20 ). In some respects, the FA core complex is similar to the SKP1-CUL1-F-box (SCF) ubiquitin ligase complex, which is involved in cell cycle regulation. The FA core complex interacts with FANCM, which is a protein that belongs to the ERCC1/XPF family of structure-specific DNA-binding proteins 50 . ICLs that are induced during S phase activate the FA core complex to monoubiquitylate two further DNA-associated factors, FANCD2 and FANCI 51, 52 , leading to their retention on chromatin 53 . In the absence of any one component of the FA core complex, ubiquitylation fails to take place -highlighting its importance as a central element of FA pathway activation.
ICL damage recognition requires FANCM when the damage is encountered by a replication fork 54 (FIG. 2) .
As such, this mechanism of ICL repair is inefficient or non-existent in cells in G1 and in non-cycling cells 55 . The replication of DNA requires DNA unwinding ahead of the DNA polymerase, which is achieved by the helicase functions of the minichromosome maintenance complex (MCM2-7) 56 . However, replication stalls when the replisome encounters an ICL because the DNA strands cannot be separated owing to the covalent linkage between the two DNA strands 57 . The resulting structure is then recognized by FANCM, which contains both a degenerate inactive carboxy-terminal ERCC4 nuclease domain that binds to branched DNA structures in vitro 58 and an internal domain that is required for interaction with the FA core complex 59 . FANCM obtains stability and specificity by interactions with another ERCC4 domain-containing protein, FAAP24, to form a FANCM-FAAP24 heterodimer 58 . Recruitment of the FA core complex to chromatin by FANCM-FAAP24 is thus limited to phases of the cell cycle in which replication is active, and recruitment is also limited by the regulated degradation of FANCM during mitosis 55, 59 . Possibly because of the interaction of FANCM with the histone-like proteins MHF1 (also known as CENPS) and MHF2 (also known as CENPX), FANCM itself is constitutively associated with chromatin 60, 61 . As the other FA proteins only enter the chromatin on replication stalling, it is likely that the interaction of FANCM and the FA core complex is further regulated. In support of this, FANCM or FAAP24 depletion leads to the loss of FANCD2-FANCI monoubiquitylation, despite normal FA core complex assembly 58, 59 .
Unlike the polyubiquitylation signals that are important for protein degradation, the monoubiquitylation of proteins alters their activity, localization or ability to form protein-protein interactions 62, 63 . It is unknown whether monoubiquitylation of FANCD2-FANCI precedes chromatin binding, or merely stabilizes their interaction with damaged sites, but the vast majority of chromatin-associated FANCD2 is in the monoubiquitylated form 64 . Recombinant FANCD2 or FANCI have both been shown to bind independently to branched DNA structures 65, 66 , suggesting that they might be capable of associating with sites of damage, such as those recognized by FANCM 65, 66 . One possibility is that FANCD2 and FANCI can transiently interact with damaged DNA, but that monoubiquitylation by the proximal FA core complex stabilizes their localization. Once the damage is repaired, the subsequent dissociation of the FA core complex would allow access to the deubiquitylating enzyme ubiquitin-specific peptidase 1 (USP1). Deactivation of the pathway following DNA damage removal seems to be equally important because the deletion of USP1 also causes an FA-like phenotype in mice 67 (although USP1 does not seem to be associated with human disease).
Recently, two proteins were shown to specifically interact with the modified form of FANCD2: Fanconiassociated nuclease 1 (FAN1) and DNA polymerase ν (Pol ν; also known as POLN) [68] [69] [70] [71] . Both proteins colocalize with FANCD2 in nuclear foci when cells are treated with agents such as MMC, but neither is required for monoubiquitylation. FAN1 has a UBZ4-type ubiquitin-binding zinc finger domain, which is required for interaction with modified FANCD2, as well as a VRR-nuclease domain. FAN1 degrades single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) exposed ends (5′-3′ exonuclease activity) and can cut DNA on the 5′ side of a ssDNA-dsDNA junction (known as 5′-flap endonuclease activity) and would therefore have an activity that is suited to cutting DNA that is adjacent to a stalled replication fork. Such cleavage is termed 'unhooking' , and may convert the stalled fork into a double-strand break (DSB). This has been the most widely supported model for the initial step in ICL 
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FANCD2
Mismatch repair (MMR). A strand-specific mechanism for editing mismatched bases inserted in the daughter strand during replication. This damage is repaired by recognition of the deformity caused by the mismatch.
Futile cycle
A DNA repair process that is repeatedly initiated, but a subsequent step re-establishes the damaged state.
repair, and it can be adapted to include two replication forks encountering the ICL 57 . The stalling of a replication fork by MMC can trigger the initiation of a new replication fork from a nearby origin 72 , which would approach the ICL from the other side. The frequency of double replication fork encounters with ICLs has never been experimentally determined, but could be presumed to increase as cells complete replication in late S phase. In the comprehensive model for ICL repair depicted in  FIG. 3 , we present mechanisms for ICL repair at each stage of the cell cycle. Given that nuclease-mediated ICL unhooking is necessary in some form at all stages of the cell cycle, followed by bypass of the crosslinked base pair by TLS DNA polymerases, it is likely that repair will require the actions of various nucleases and DNA polymerases.
Nucleases and polymerases in ICL repair
Hints regarding the importance of specific nucleases in ICL repair have come from individuals with biallelic mutations in ERCC4 (which encodes XPF), ERCC1 and SLX4. Hypomorphic mutations in ERCC4 cause the ultraviolet (UV) radiation-sensitive disorder xeroderma pigmentosum (XP), whereas biallelic ERCC4 or ERCC1 mutations lead to a premature ageing syndrome known as XPF/ERCC1 progeroid syndrome that causes sensitivity to ICLs 73, 74 . SLX4 mutations cause a more typical FA phenotype, and the gene has recently been designated FANCP on the basis of the identification of FA families with biallelic mutations in this gene 75, 76 . FAN1 and the heterodimeric nucleases MUS81-EME1, XPF-ERCC1 and SLX1-SLX4 are all required to prevent sensitivity to nitrogen mustards, MMC or platinum drugs 50, 77, 78 . These three endonucleases are specific for 3′-flap structures, which, combined with the 5′-flap activity of FAN1, could result in the cleavage of the DNA backbone on both sides of an ICL. Interestingly, SLX1-SLX4, MUS81-EME1 and XPF-ERCC1 have been shown to form a 'supercomplex' that can be co-immunoprecipitated from cells 78 ; this makes it difficult to determine which particular nuclease promotes cleavage at an ICL. The possible involvement of these nucleases in downstream events, such as in the resolution of recombination intermediates, provides a further complication [79] [80] [81] . One possibility is that these different nucleases exist to deal with diverse forms of DNA crosslinks -such as crosslinks that distort the DNA double helix, as well as those that do not distort the DNA double helixand there may be particular requirements for different nucleases according to the stage in the cell cycle at which an ICL is encountered. For example, it has been shown that the amount of unhooking present in G1 phase is directly influenced by the degree of ICL-induced helical distortion 82 . XPF-ERCC1 could cleave DNA adjacent to ICLs that substantially distort the DNA double helix in G1, in much the same way as they cut adjacent to damaged nucleotides that distort DNA during NER 50 . SLX4 could also be recruited to distorting ICLs in G1 by its direct interaction with the mismatch repair (MMR) complex MUTSβ 78, 83, 84 . The importance of helix distortion in ICL repair has been addressed using cell-free systems and plasmids containing different types of ICLs. Lesions that result in little helix distortion are only repaired in replicationcompetent extracts, whereas the repair of helix-distorting ICLs can also be detected in non-replicating plasmid DNA 57, 85 . Genetic and toxicity studies suggest that even for highly distorting lesions, such as those that are induced by platinums, not all ICLs are repaired in G1 (REFS 86, 87) . One possibility is that these distorting lesions are not detected in the context of highly condensed heterochromatic DNA or in regions of the genome that are non-B-form DNA, such as upstream promoter elements 88 . Some of this damage could also undergo a futile cycle of repair, involving NER and TLS enzymes that mediate the nucleolytic cleavage of ICLs during G1 but are unable to complete the removal of In cells in G1 phase of the cell cycle, nucleotide excision repair (NER) can remove a subset of interstrand crosslinks (ICLs). Excision by XPF-ERCC1 is followed by translesion synthesis, and excision of the 'flipped out' ICL. However, some lesions cannot be bypassed in this manner and a futile cycle of repair involving excision and ligation occurs. During S phase, a partially processed intermediate may be encountered by a replication fork, which leads to the collapse of the replication fork and the formation of a one-ended double-strand break (DSB). These collapses are probably avoided by FANCM-mediated fork regression and stabilization of the fork by the Fanconi anaemia (FA) pathway. This FA-stabilized homologous recombination (HR) intermediate (highlighted by beige circles) allows the nascent leading strand of DNA synthesis (indicated by a green arrow) to be extended by translesion synthesis polymerases (Pol; black dashed arrow). Unhooking of the ICL by coordinated incision by the 5′-and the 3′-flap endonucleases allows extension past the lesion. HR is then completed and replication can be re-established. If a second replication fork has encountered the ICL from the opposite direction, unhooking on the 3′ side cuts the leading strand template. The extension of the 'left-hand' leading strand would lead to its joining with the lagging strand of the right-hand fork, followed by second end capture and extension of the right-hand leading strand and the left-hand template strand. This process would complete replication without the re-initiation of lagging strand synthesis but would generate a double Holliday junction. This structure is resolved by the BLM-containing complex or may in some instances be cut by structure-specific nucleases (not shown). FAN1, Fanconi-associated nuclease 1.
the covalently linked bases 87 (FIG. 3) . These cleavage events would persist into S phase, leading to the direct collapse of the replication fork when it encounters the nicked DNA. HR would then repair this collapsed fork in a scenario that is similar to that in which canonical S phase ICL repair is initiated.
The encounter of an ICL by the replication fork leads to nuclease recruitment by mechanisms that are different from those that occur in G1. FAN1 is recruited to stalled replication forks by monoubiquitylated FANCD2 (REF. 70 ), and SLX4 could be recruited directly to the vicinity of DNA damage by its tandem UBZ domains 76 that interact directly with K63-linked ubiquitin chains, which themselves represent markers of stalled replication 76, 89 . Finally, MUS81 and XPF are relocalized as part of the SLX4 complex 90 . This regulated recruitment of nucleases by ubiquitylated proteins might suggest a mechanism that orients cleavage on the basis of the localization of the ubiquitylated protein in relation to the DNA substrate. In an environment such as that found at an ICL between two converging replication forks (FIG. 3) , there are many potential nucleolytic substrates, so the careful regulation of DNA cleavage will be essential.
After unhooking, the nascent DNA strand must be extended past the lesion but normal replicative DNA polymerases are incapable of extension when the replisome is blocked by a crosslink 91 (as opposed to the situation with base damage in which the MCM helicase and polymerase can be uncoupled 92 ). The replication fork may be stabilized by HR (see below) and lesion bypass will require the TLS polymerases (reviewed in REF. 93 ).
Xenopus laevis extracts that are capable of replication have provided a useful model system for studying the repair of a single platinum crosslink, and these studies indicate that the replicative polymerase stalls about 24 nucleotides before the crosslink. At this site, a switch to TLS is presumed to take place, and this may involve Pol ν, which extends the nascent strand to within 1 base pair of the ICL before unhooking takes place 57 . Such a switch would be more difficult if the replication fork had collapsed much earlier owing to unhooking before replication. TLS requires the monoubiquitylation of the replication-associated factor proliferating cell nuclear antigen (PCNA) on K164, a step that also stimulates the activation of the FA pathway through FANCD2 recruitment 94, 95 . After unhooking, the deoxycytosine monophosphate (dCMP) transferase REV1 can insert a cytosine into the nascent strand opposite the unhooked ICL 96, 97 . One of several other TLS polymerases may then be responsible for the extension of the nascent DNA beyond the crosslinked base pair still present in the DNA double helix. Although many of these polymerases can extend the nascent strand beyond the crosslink (reviewed in REF. 98 ), only depletion of Pol ζ seems to abrogate TLS extension in X. laevis extracts 57 . Consistent with this summary, only Pol ν, REV1 and Pol ζ are essential for ICL repair, and, owing to the error-prone nature of the reactions they promote, their involvement is potentially mutagenic 71, 99 .
The role of HR in ICL repair
Extremely positive results have been obtained with the ICL-inducing agent carboplatin in early phase clinical trials for the treatment of triple-negative breast cancers -those that do not express HER2 (also known as ERBB2) or oestrogen and progesterone receptors and that are most likely to be associated with alterations in BRCA1 or BRCA2 (REF. 100 ). Platinum drugs are also beneficial when used as single agents in the treatment of BRCA1-and BRCA2-associated ovarian cancers 101 . The protein products of these two genes are important for HR-mediated repair of DNA damage. BRCA1, in combination with BRCA1-associated RING domain protein 1 (BARD1), exhibits ubiquitin ligase activity 102 that is necessary for the proper localization of RAD51, a central player in HR; BRCA2 interacts directly with RAD51 and promotes its specific targeting to sites where recombination is initiated 103, 104 . RAD51-deficient cells, like the tumour cell lines derived from patients with BRCA1 and BRCA2 alterations, are hypersensitive to ICL-inducing agents 105, 106 . This observation further supports a role for HR in ICL repair.
The process of HR during ICL repair requires the generation of a DSB, because RAD51 nucleoprotein filament formation requires a free DNA end and single-stranded regions in order to stimulate the search for homology on the adjacent DNA strand 107 . γH2AX is a biomarker of nuclear DSBs in patients receiving chemotherapy, and can be measured in hair follicles that are extracted at various times after treatment 108 . Several potential sources of DSBs exist during the processing of an ICL. As discussed above, the nuclease-mediated unhooking of an ICL can occur either before encountering the replication fork -leading to the collapse of the replication fork into a one-ended DSB -or after the switch to TLS and the progression of the replication fork to within 1 base pair of the ICL 57 . Alternatively, the stalled replication fork may regress to form a 'chicken foot' structure at the site of the ICL to generate a free dsDNA end (FIG. 3) . FANCM has been shown to promote fork regression in vitro 109 , and chicken foot structures have been shown to exist in vivo and in vitro 110, 111 . Replication fork stabilization after formation of a chicken foot structure occurs through the recombination of the nascent regressed arm into homologous sequences ahead of the fork (FIG. 3) .
Although the process of HR at a two-ended DSB (such as that caused by ionizing radiation) is well characterized (reviewed in REF. 107 ), there are important differences when HR takes place at a stalled replication fork. First, the association of the replication complex with the nascent DNA molecules that are adjacent to the break may facilitate recombination with the correct template sequences rather than with related, but incorrect, target sequences. Second, the MRE11-RAD50-nibrin (NBS1; known as the MRN complex) nuclease, which is normally required for end resection, is inhibited by RAD51, probably because extensive resection at a replication fork is unnecessary or potentially deleterious 112 . that form during the repair process. For example, cells that are deficient in the RAD51-paralogue RAD51C (also known as FANCO) are sensitive to ICL-inducing agents, and this protein may have a more important role in the repair of a one-ended, rather than a twoended, DSB 113, 114 . RAD51C, like BRCA1, BRCA2 and BRCA1-interacting protein 1 (BRIP1; which encodes FANCJ), was recently shown to be a breast and ovarian cancer predisposition gene in heterozygous carriers, and it causes an FA-like syndrome when homozygously mutated 31, 115 . The HR step of ICL repair (and probably other replication-fork stalling lesions) may thus be one of the most important tumour suppressive roles of BRCA1 and BRCA2.
The completion of HR requires 'second end capture' and extension of the template strand by a DNA polymerase. The identity of the polymerase that carries out this DNA synthesis step is currently unknown, but after encountering a single replication fork this polymerase will promote replication restart. In the 'late-S phase model' , when two forks converge on an ICL (FIG. 3) , second end capture and extension will lead to the completion of replication and the formation of a double Holliday junction (DHJ) that can be dissolved by the BTR complex (comprised of the BLM RecQ helicase, topoisomerase IIIα (TOPOIIIα), RecQ-mediated genome instability 1 (RMI1) and RMI2) in a reaction that avoids sister chromatid exchanges (SCEs) 116, 117 . BLM is mutated in Bloom's syndrome, a disorder that is similar to FA in many respects. Consistent with this, the BTR complex associates with the FA core complex, providing a direct link between the upstream signalling of ICL damage recognition and the downstream resolution of the HR products 59, 118 . A characteristic feature of Bloom's syndrome cells is an elevated frequency of SCEs, and these levels are further increased by treatment with MMC 119 . It was recently shown that, in the absence of BLM, DHJs are resolved by the MUS81-EME1, SLX1-SLX4 and GEN1 endonucleases that promote SCE formation 81 . Strikingly, genetic exchanges between homologous chromosomes are also highly elevated in BLM-deficient cells, resulting in loss of heterozygosity 120 , a hallmark feature of tumorigenesis. High doses of ICL-inducing agents in wild-type cells also lead to increased SCE levels 121 , suggesting that the nucleolytic cleavage pathway of Holliday junction resolution occurs when BLM function is normal but when the levels of DNA damage are saturating. By promoting the BLM-mediated pathway during ICL repair, there is less chance of both SCE formation and crossing over between homologous chromosomes. The high tumour incidence in patients with Bloom's syndrome (which includes a broader range of cancer types than those associated with FA) reflects the importance of this component of the repair process.
Suppression of NHEJ reduces ICL sensitivity
Although HR promotes error-free DSB repair in S phase, an alternative mechanism that is known as nonhomologous end joining (NHEJ) exists to repair broken DNA in all phases of the cell cycle. NHEJ uses a simple splice mechanism to rejoin the two free ends of DNA. The process is initiated by binding of the KU70-KU80 heterodimer to the free dsDNA ends and involves the activation of downstream steps by the binding of DNA-dependent protein kinase catalytic subunit (DNAPKcs) 122 . DNA is processed to remove any 5′-or 3′-ssDNA tails, and the resulting end is directly rejoined with a similarly processed sequence by DNA ligase IV-XRCC4 (reviewed in REF. 123 ). Unlike HR, in which homologous sequences are used to proofread the repair process, NHEJ is capable of generating deletions, insertions and translocations when incorrect ends are rejoined.
Human cells that are defective for KU70, KU80, DNA-PKcs, DNA ligase IV or XRCC4, are insensitive to MMC, platinums or other ICL-inducing drugs, confirming studies in yeast and mice showing that the NHEJ pathway is not required for ICL repair 124, 125 . However, recent reports have shown that the inhibition of the NHEJ pathway in cell lines derived from patients with FA can reduce the toxicity of ICL-inducing drugs. For example, in chicken or nematode knockout models, specific FA-like defects can be rescued by the co-deletion of KU70 or ligase IV 126, 127 . Furthermore, in FANCA-and Because the DSB is one ended, NHEJ does not have a natural substrate to rejoin so these breaks can remain unrepaired (generating chromatid breaks) or may ligate with a DSB in a different chromosome (generating radial chromosomes). Suppression of NHEJ by deleting a component of this pathway or by using DNA-dependent protein kinase catalytic subunit (DNA-PKcs) inhibitors promotes the repair of the DSBs by FA-independent pathways of HR (dashed arrow).
Cytopenias
Loss of one or multiple types of white or red blood cells, which is often caused by the depletion of stem cell pools.
Cell cycle checkpoints
A control mechanism that prevents cell cycle continuation in the presence of damaged, unreplicated or incompletely segregated DNA.
FANCD2-deficient human cells, the high sensitivity to MMC can be rescued through the simultaneous inhibition of NHEJ by the DNA-PKcs inhibitor NU7026 (REF. 127 ). Analysis of mitotic spreads from these cells shows that the atypical radial chromosomes that are seen in FA cells are only rarely found when NHEJ is inactivated. These observations indicate that a major function of the FA pathway in ICL repair is to suppress spurious ligation of ICL-induced DSBs between non-homologous chromosomes (FIG. 3) .
For the repair of de novo DSBs (such as those caused by ionizing radiation) HR and NHEJ provide complementary functions, and co-inhibition of HR and NHEJ leads to increased cell death [128] [129] [130] . However, FA cells are not defective in HR per se, so the inhibition of NHEJ in FA cells still allows them to proliferate and repair DSBs (FIG. 4) . This is because the FA pathway only promotes HR at stalled replication forks, by stabilizing the intermediate that is required for unhooking and TLS. HR can still occur if the replication fork is not stabilized, but the free DNA end that is generated is more likely to be bound by KU70-KU80, which has a very high affinity for such structures 131, 132 . KU70-KU80 promotes NHEJ with the correct adjacent sequence only some of the time, but causes the formation of radial structures if it promotes ligation with sequences on another broken chromosome 133 . By inhibiting the NHEJ pathway, the less active, but also less toxic, FA-independent HR pathway can re-establish the replication fork (FIG. 4) . Ongoing work aims to test the efficacy of NHEJ inhibitors in diluting the severity of FA-like phenotypes in FA mouse models, but these drugs could have a wider use in the protection from ICL toxicity in the blood of patients treated with chemotherapies.
Modulating ICL sensitivity: protect and destroy As platinums and alkylating agents currently represent some of our most successful chemotherapeutic agents, the ability to change cell sensitivity to these drugs could have enormous therapeutic implications. As outlined in TABLE 1, the therapeutic window for ICL-based chemotherapy is restricted by dose-limiting toxicities in the blood: therefore, being able to specifically activate haematopoietic ICL resistance could theoretically raise the maximum tolerated dose. In patients with FA, a potential strategy to prevent developmental cytopenias may be the use of inhibitors of NHEJ (such as the DNA-PKcs inhibitor NU7026), but it remains to be seen whether such an approach would also protect the blood of wild-type patients undergoing chemotherapy. Current clinical practice involves the use of recombinant cytokines granulocyte colony-stimulating factor (G-CSF; known as filgrastim) and granulocytemacrophage CSF (GM-CSF; known as sargramostim) to promote the mobilization of haematopoietic stem cells to try and recover the cells lost by ICL-induced apoptosis 134 . These agents are normally given in the recovery phase, and most ICL-induced cytopenias can be rescued in this manner. However, when given concurrently with crosslinking drugs, these cytokines may actually potentiate cytopenia 135 , as stem cells that are induced to proliferate may be more sensitive to DNA damage than quiescent cells 136 . It is therefore reasonable to suggest that the prevention of cytopenias may benefit from an understanding of how tumour cells become resistant to ICLs, and in applying this knowledge to promote resistance in the non-diseased cells of the blood.
One mechanism of resistance to ICL-inducing drugs is the accelerated removal of DNA adducts. Such activities have been detected in ovarian and testicular tumours that become resistant after chronic cisplatin exposure, and this is often associated with elevated levels of XPF-ERCC1, MUS81-EME1 and FA proteins [137] [138] [139] [140] [141] . FANCFdependent resistance to cisplatin leads to increased cross-resistance to MMC 139 , and larger studies have identified a general pattern of cross-resistance after exposure to just one type of ICL-inducing drug 142 . The development of methods that increase ICL repair in normal tissue might lead to effective chemoprotection.
Conversely, as resistance to ICL-inducing drugs develops, targeted inactivation of ICL repair represents a tumour control strategy. An indirect mechanism of downregulating elevated ICL repair in tumour cells is mediated by the inhibition of extracellular signalling pathways, although little is understood about this mechanism. For example, the HER2 antibody trastuzumab can suppress the repair of cisplatin adducts in cell cultures 143 and can potentiate cisplatin and melphalan treatments in breast cancer [144] [145] [146] . Trastuzumab may function indirectly to affect cell cycle checkpoints, and the direct targeting of checkpoint kinases has also shown some clinical promise.
The checkpoint kinase CHK1 suppresses exit from G2 phase into mitosis by phosphorylating several key cell cycle proteins 147 . This G2 cell cycle checkpoint is necessary to allow time to repair DNA damage, particularly when the G1 phase, p53-dependent cell cycle checkpoint is absent, as it is in most tumour cells. The absence of both cell cycle checkpoints allows p53-mutant tumour cells to enter mitosis even though they have extensive DNA damage. These cells die by a process known as mitotic catastrophe -death occurs not by the defined pathway of apoptosis, but by the loss of genetic material that is essential for survival 148 . This strategy may be particularly potent in re-establishing sensitivity to ICLinducing drugs in tumours because the mechanism of death is apoptosis-independent and the catastrophe can be accentuated by larger amounts of unrepaired DNA damage. In this manner, strategies that include CHK1 inhibition, or MAPK inhibition (MAPK participates in a parallel pathway to CHK1 in G2) have shown promise in re-establishing cisplatin sensitivity in in vitro models 149, 150 .
Concluding remarks
Over the past decade, rapid advances have been made in understanding how ICL damage is repaired following chemotherapy. We now know that ICL repair involves a complex coordination of NER, HR and TLS, as well as the suppression of NHEJ. But information is still missing, and this has meant that the translation of knowledge into the improved clinical use of ICL-damaging agents remains in its infancy. Some investment has been made in improving cell killing by these drugs, such as for use in BRCA1-deficient breast cancers 101 , but the core dose-limiting toxicity of ICL-inducing agents -the damage to the haematopoietic system that was ironically first seen in the casualties of the Bari disaster nearly 70 years ago -has generally been ignored. Overcoming this toxicity will allow greater therapeutic windows, and reduced side effects in patients. Increased tumour cell killing by using higher doses of ICL-inducing drugs may also limit the development of tumour resistance. Further investigation into FA, and other model diseases, may uncover the last remaining players in ICL repair, but a concerted effort to understand the precise mechanistic details of events that occur when the FA pathway is activated will undoubtedly provide key insights regarding the use of DNA crosslinking agents in chemotherapy.
